First Patient Dosed in Ph 1/2 Trial of PFL-241/STX-241 in Locally Advanced or Metastatic NSCLC patients
“The initiation of the second clinical trial in partnership with Pierre Fabre Laboratories is an important milestone as we work together to enable the rapid, global advancement of our next-generation EGFR inhibitors for difficult-to-treat NSCLC patients,” said Mark Chao, M.D., Ph.D., Chief Medical Officer of Scorpion. “PFL-241/STX-241 is a novel, CNS-penetrant and highly potent and selective treatment option for patients who develop ‘double mutant’ disease for which there is currently no approved treatment, and it’s a pleasure to partner with Pierre Fabre Laboratories, a company who shares our commitment to bringing innovative treatments to this underserved patient population. We look forward to demonstrating how PFL-241/STX-241’s differentiated preclinical profile translates into clinical benefit for patients.”
Share:
More News
“Initiation of the TEADCO Phase 1b/2 basket trial is another important milestone for the ODM-212 clinical development program and reflects our commitment to patients with difficult-to-treat cancers,” said Professor Outi Vaarala, Executive Vice President, Research & Development at Orion. “Together with the ongoing TEADES study, TEADCO highlights the versatility of
“In this study, tovecimig showed an impressive overall response rate which translated into a clinically meaningful and highly statistically significant improvement in PFS for patients with previously treated BTC. The remarkable 56% reduction in the risk of disease progression is unprecedented in this patient population without an actionable mutation in
“We are encouraged to see taletrectinib (IBTROZI) added to the NCCN Guidelines® for CNS Cancers given its demonstrated high rates of intracranial response that are durable in ROS1+ NSCLC patients with brain metastases,” said David Hung, M.D., Founder, President and Chief Executive Officer of Nuvation Bio. “Given the prevalence of
Daniel Getts, Ph.D., CEO of CREATE, added “MT-304 is proof of what our platform can do, and what our team can execute. Our mRNA-LNP leadership enables us to move from concept to clinic with remarkable speed. Just last weekend at AACR, we presented compelling preclinical data across our in vivo